NEW YORK (GenomeWeb News) – The drug discovery company Chemizon has struck a strategic partnership with the clinical research company Crown Biosciences to offer a number of drug research capabilities, including proteomics and biomarker services, Chemizon said today.
 
Chemizon, which is a division of Optomagic, also said it has made an investment in CrownBio of an undisclosed amount through a private equity fund. 
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.